Werewolf Therapeutics, Inc.Werewolf Therapeutics, Inc.Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪116.89 M‬USD
‪−37.37 M‬USD
‪19.94 M‬USD
‪30.01 M‬
Beta (1Y)

About Werewolf Therapeutics, Inc.

Daniel J. Hicklin
Employees (FY)
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.
Revenue to profit conversion
Debt level and coverage
Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of HOWL is 2.69 USD — it has decreased by 1.82% in the past 24 hours. Watch Werewolf Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Werewolf Therapeutics, Inc. stocks are traded under the ticker HOWL.
HOWL stock has risen by 27.49% compared to the previous week, the month change is a 16.20% fall, over the last year Werewolf Therapeutics, Inc. has showed a 14.90% decrease.
We've gathered analysts' opinions on Werewolf Therapeutics, Inc. future price: according to them, HOWL price has a max estimate of 15.00 USD and a min estimate of 9.00 USD. Watch HOWL chart and read a more detailed Werewolf Therapeutics, Inc. stock forecast: see what analysts think of Werewolf Therapeutics, Inc. and suggest that you do with its stocks.
HOWL reached its all-time high on Apr 30, 2021 with the price of 23.99 USD, and its all-time low was 1.39 USD and was reached on Dec 7, 2022. View more price dynamics on HOWL chart.
See other stocks reaching their highest and lowest prices.
HOWL stock is 14.12% volatile and has beta coefficient of 0.18. Track Werewolf Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Werewolf Therapeutics, Inc. there?
Today Werewolf Therapeutics, Inc. has the market capitalization of ‪116.90 M‬, it has increased by 5.77% over the last week.
Yes, you can track Werewolf Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Werewolf Therapeutics, Inc. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
HOWL earnings for the last quarter are −0.39 USD per share, whereas the estimation was −0.34 USD resulting in a −14.04% surprise. The estimated earnings for the next quarter are −0.38 USD per share. See more details about Werewolf Therapeutics, Inc. earnings.
Werewolf Therapeutics, Inc. revenue for the last quarter amounts to ‪742.00 K‬ USD, despite the estimated figure of ‪1.46 M‬ USD. In the next quarter, revenue is expected to reach ‪841.78 K‬ USD.
HOWL net income for the last quarter is ‪−16.19 M‬ USD, while the quarter before that showed ‪−12.00 M‬ USD of net income which accounts for −34.91% change. Track more Werewolf Therapeutics, Inc. financial stats to get the full picture.
No, HOWL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 13, 2024, the company has 47.00 employees. See our rating of the largest employees — is Werewolf Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Werewolf Therapeutics, Inc. EBITDA is ‪−43.30 M‬ USD, and current EBITDA margin is −194.25%. See more stats in Werewolf Therapeutics, Inc. financial statements.
Like other stocks, HOWL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Werewolf Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Werewolf Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Werewolf Therapeutics, Inc. stock shows the sell signal. See more of Werewolf Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.